id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6380-0019,FDA,FDA-2017-D-6380,Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry,Other,Guidance,2018-07-27T04:00:00Z,2018,7,2018-07-27T04:00:00Z,,2024-11-07T01:04:06Z,,1,0,09000064835699a6
FDA-2017-D-6380-0018,FDA,FDA-2017-D-6380,Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases; Guidance for Industry; Availability,Notice,Guidance,2018-07-27T04:00:00Z,2018,7,2018-07-27T04:00:00Z,,2018-07-27T16:35:26Z,2018-16027,0,0,09000064835678c5
FDA-2017-D-6380-0005,FDA,FDA-2017-D-6380,Guidance: Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases,Notice,Request for Comments,2018-01-12T05:00:00Z,2018,1,2018-01-12T05:00:00Z,2018-02-19T04:59:59Z,2018-02-19T02:00:39Z,2018-00418,0,0,0900006482dead2d
FDA-2017-D-6380-0003,FDA,FDA-2017-D-6380,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA),Other,Request for Extension,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2017-12-26T20:04:43Z,,0,0,0900006482d50ee2
FDA-2017-D-6380-0002,FDA,FDA-2017-D-6380,"Clarification of Orphan Designation of Drugs and Biologics for Pediatric
Subpopulations of Common Diseases Draft Guidance for Industry",Other,Guidance,2017-12-20T05:00:00Z,2017,12,2017-12-20T05:00:00Z,2018-01-20T04:59:59Z,2024-11-07T01:16:12Z,,1,0,0900006482d3f8ae
FDA-2017-D-6380-0001,FDA,FDA-2017-D-6380,"Clarification of Orphan Designation of Drugs and Biologics for Pediatric
Subpopulations of Common Diseases; Draft Guidance for Industry;
Availability",Notice,Notice of Availability,2017-12-20T05:00:00Z,2017,12,2017-12-20T05:00:00Z,2018-01-20T04:59:59Z,2018-01-20T02:02:49Z,2017-27435,0,0,0900006482d3f50b